Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
ENTELLUS MEDICAL INC (ENTL) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/01/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 1, 2017 ENTELLUS MEDICAL, INC. Delaware 001-36814 20-4627978 3600 Holly Lane North, Suite 40 Plymouth, Minnesota 55447 463-1595 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to R...",
"ENTELLUS MEDICAL ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS"
08/03/2017 8-K Quarterly results
Docs: "ENTELLUS MEDICAL ANNOUNCES SECOND QUARTER 2017 FINANCIAL RESULTS PLYMOUTH, MN. - Entellus Medical, Inc. , a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis, nasal airway obstruction and persistent Eustachian tube dysfunction, today reported its financial results for the quarter ended June 30, 2017. Recent Highlights and Accomplishments"
05/03/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
08/03/2016 8-K Form 8-K - Current report
05/04/2016 8-K Quarterly results
Docs: "ENTELLUS MEDICAL ANNOUNCES FIRST QUARTER 2016 FINANCIAL RESULTS PLYMOUTH, MN. - Entellus Medical, Inc. , a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today reported its financial results for the quarter ended March 31, 2016. Recent Highlights and Accomplishments • Revenue of $16.9 million in the first quarter of 2016, an increase of 25% year-over-year • Pediatric uptake in the first quarter reflects positive physician reception and adoption • Achieved balanced revenue growth across ENT offices and ORs, with In-Office revenue representing 54% of U.S. product revenue in the first quarter “We are off to a strong start in 2016 with continu..."
11/09/2015 8-K Quarterly results
Docs: "ENTELLUS MEDICAL ANNOUNCES THIRD QUARTER 2015 FINANCIAL RESULTS INCREASES FULL YEAR REVENUE GUIDANCE PLYMOUTH, MN. - Entellus Medical, Inc. , a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today reported its financial results for the quarter ended September 30, 2015. Recent Highlights and Accomplishments"
08/06/2015 8-K Quarterly results
Docs: "ENTELLUS MEDICAL ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS PLYMOUTH, MN. - Entellus Medical, Inc. , a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today reported its financial results for the quarter ended June 30, 2015. Recent Highlights and Accomplishments"
05/07/2015 8-K Quarterly results
Docs: "ENTELLUS MEDICAL ANNOUNCES FIRST QUARTER 2015 FINANCIAL RESULTS"
04/02/2015 8-K Quarterly results
Docs: "Letter Agreement with Brian E. Farley",
"ENTELLUS MEDICAL ANNOUNCES PROMOTION OF ROBERT WHITE TO CHIEF EXECUTIVE OFFICER, AND PRELIMINARY FIRST QUARTER 2015 REVENUES OF $13.4 TO $13.5 MILLION PLYMOUTH, MN. - Entellus Medical, Inc. , a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, announced that effective today, Robert White, President and Chief Operating Officer of the Company has been promoted to President and Chief Executive Officer and appointed to its Board of Directors. In a planned move, Brian Farley, the Company's current Chairman and Chief Executive Officer, has transitioned to Executive Chairman of the Board and part-time employment with the ..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy